Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant …

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor
quality of life, morbidity and mortality. Its incidence and associated healthcare costs are …

Background There is no recommended therapy for malignant pleural mesothelioma that has
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …

Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

Background The current staging system for malignant pleural mesothelioma (MPM) is
controversial. To plan revisions of this system, the International Association for the Study of …

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to
asbestos. Patients with malignant pleural mesothelioma have poor outcomes with …

Background The use of prophylactic radiotherapy to prevent procedure-tract metastases
(PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies …

Purpose Mesothelin is currently considered the best available serum biomarker of malignant
pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in …